Abstract:Background: p53 mutations are highly frequent in various human cancers and are reported to contribute to tumor malignance and chemoresistance. In this study, we explored the mechanism by which mutant p53 promotes carcinogenesis and chemoresistance and provided novel insights into cancer therapy.Materials and methods: A total of 409 patients with colorectal carcinoma from TCGA database were subdivided into two groups according to the p53 status, namely, mutant p53 and wild-type p53, following with GSEA analysis. The differences of the clinicopathologic index were also analyzed. Two HCT116 cell lines containing hot spots at codons R273H and R248W of p53 were constructed based on HCT116 with knockout p53, respectively. Cell viability, mobility, clonogenesis, and stemness were detected by CCK8, transwell migration and invasion, colonogenic, and sphere formation assays. Resistance to 5-FU was examined by live-dead staining and flow cytometry. qPCR, Western blot, and luciferase reporter assay were performed to identify that deficient or mutant p53 promoted chemoresistance of the colorectal carcinoma cell line HCT116 through the TCF21/CD44 signaling pathway, with the following rescue assays by overexpression of TCF21 and knockdown of CD44.Results: Patients with recurrence harbor a higher frequency of mutant p53 than those without recurrence (p < 0.05). The mutant p53 group developed a larger tumor than the wild-type one. GSEA analysis showed that oncogenic signatures were enriched in the mutant p53 group. Extracellular assays showed that cancer cells with deficient or mutant p53 (R273H and R248W, respectively) promoted colon cancer cell growth, migration, invasion, and stemness. The mutant cancer cells were also observed to be significantly resistant to 5-FU. Xenografts also confirmed that HCT116 cells harboring deficient or mutant p53 promoted cancer growth and 5-FU tolerance. Luciferase reporter assay showed that deficient or mutant p53 R237H and R248W endowed cancer cells with chemoresistance by activating CD44 via repressing the nuclear transcription factor TCF21 expression. Overexpression of TCF21 or knockdown of CD44 could rescue the sensitivity to 5-FU in deficient and mutant p53 HCT116 cell lines.Conclusion: Our results, for the first time, reveal a novel deficient or mutant p53/TCF21/CD44 signaling pathway which promotes chemoresistance in colorectal carcinoma. The axis could be an effective therapeutic strategy against deficient- or mutant p53-driven chemoresistance.

WTP53 Gene Combined with TK and CD Inhibited the Growth of Colon Carcinoma Cell Line SW480

Effects of Different Chemotherapeutic Agents on Reversing the Acquired Resistance to TRAIL Gene in DLD1 Colon Cancer Cells

Relation Between Mutant P53 and Multidrug Resistance in Gastric Cancer

Inhibitory Effect of Platycodin D on Human Colonic Cancer SW620 Cell Proliferation

Study on relationship between mutant p53 and multidrug resistance gene 1 in gastric cancer

In vitro synergistic cytotoxic effect of triptolide combined with hydroxycamptothecin on pancreatic cancer cells.

Synergistic suppression effect on tumor growth of hepatocellular carcinoma by combining oncolytic adenovirus carrying XAF1 with cisplatin

Less Cytotoxicity to Combination Therapy of 5-Fluorouracil and Cisplatin Than 5-Fluorouracil Alone in Human Colon Cancer Cell Lines.

Tumor Suppression Activity of Ginsenoside Rg3 Combined with TRAIL Gene on Human Colon Cancer Cell Line HCE8693

Inhibition of Expression of Vascular Endothelial Growth Factor and Its Receptors in Pulmonary Adenocarcinoma Cell by TNP-470 in Combination with Gemcitabine

EFFECT OF RECOMBINANT ADENOVIRUS-p53 COMBINED WITH DOCETAXEL ON THE GROWTH INHIBITION OF HUMAN LUNG ADENOCARCINOMA CELL LINES

In vitro antitumor effect of CD, TK fusion suicide gene induced by adenovirus vector

Effect of transfection of wild-type p53 gene on sensitivity of T cell lymphoma to chemotherapy

[Effect of Recombinant Adenovirus-P53 on Growth and Chemosensitivity of Human Lung Adenocarcinoma Cell Lines].

WGCNA Reveals Key Gene Modules Regulated by the Combined Treatment of Colon Cancer with PHY906 and CPT11.

Effect of Adenovirus-mediated Wild-Type P53 Gene Transfection on the Growth and Radiosensitivity of Human Lung Adenocarcinoma Cells

Double Lethal Effects of Fusion Gene of Wild-type P53 and JunB on Hepatocellular Carcinoma Cells

The Antitumorigenic Effects of Wild-Type P53 on Human Colon Adenocarcinoma Cells

Deficient or R273H and R248W Mutations of p53 Promote Chemoresistance to 5-FU <i>via</i> TCF21/CD44 Axis-Mediated Enhanced Stemness in Colorectal Carcinoma

Inactivation Of P53 Increases The Cytotoxicity Of Camptothecin In Human Colon Hct116 And Breast Mcf-7 Cancer Cells

CCT6A promotes cell proliferation in colon cancer by targeting BIRC5 associated with p53 status